MAPT and Alzheimer disease: Given the remarkable power of the sMRI modality to capture robust atrophy signatures of AD pathology (Rathore et al. 2017) and its other crucial advantages of being noninvasive, more readily accessible than PET, and comprehensively supported by health insurance, it can be potentially leveraged to derive amyloid and tau pathology signatures in a noninvasive manner (Park and Moon 2016).